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Available online 7 February 2015AbstractAims: The high objective response rate to cetuximab along with chemotherapy in patients with colorectal liver metastases makes it an effective
downsizing protocol to facilitate surgery in those with initially unresectable disease. Adoption of this strategy has been variable in the UK. A
retrospective observational study was conducted in 7 UK specialist liver surgical centres to describe the liver resection rate following a down-
sizing protocol of cetuximab and chemotherapy and to evaluate the quality and efficiency of processes by which the treatment was provided.
Methods: Data were collected in 2012 by reviewing medical records of patients with colorectal metastases confined to the liver, defined as
unresectable without downsizing therapy at first review by a specialist Multi Disciplinary Team (MDT).
Results: Sixty patients were included; 29 (48%) underwent liver resection following cetuximab and chemotherapy. Of the 29, 17 (59% or
28% of all patients) achieved R0 resection and 7 (24% or 12% of all patients) R1 resection. All treated patients were KRAS wild-type.
Conclusion: In specialist liver surgical centres, where patients are evaluated for liver resection, optimal management by MDT using KRAS
testing, cetuximab and chemotherapy results in a 28%R0 resection rate in patients with initially unresectable colorectal cancer livermetastases.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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management of patients with previously unresectable
metastatic colorectal cancer treated with downsizing
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Downsizing chemotherapy to facilitate resection of
otherwise unresectable liver metastases from colorectal
cancer has been widely studied and is a safe and effective
strategy to improve the prognosis of patients with colo-
rectal metastases confined to the liver.1,2
The addition of targeted biological agents such as cetux-
imab to chemotherapy regimens is a promising recent
development in the available therapeutic options.3 UK
Technology Appraisal bodies have recommended cetuxi-
mab for use in the National Health Service (NHS) along
with chemotherapy as a downsizing treatment for patients
with KRAS wild-type (wt) metastatic colorectal cancer
(mCRC) and otherwise unresectable liver metastases.4,5
Subsequent to this study being conducted, in Dec 2013
the licence for cetuximab was updated to exclude patients
that harbor additional KRAS and NRAS mutations (exons
2, 3 and 4 of KRAS and NRAS) which are negative predic-
tors of outcome to cetuximab. Cetuximab is now indicated
in patients with RAS wt metastatic colorectal cancer.6
The technology appraisals of cetuximab for downsizing
unresectable liver metastases were based on evidence from
the CELIM study7 which showed that cetuximab added to
either FOLFOX or FOLFIRI regimens yielded high resec-
tion rates (34% achieved R0 resection) and improved
response rates in relation to historical controls. More
recently, Ye et al. have shown improved resectability
(26% R0 resection rate), response rates and survival with
the addition of cetuximab to conventional chemotherapy
in a study directly comparing cetuximab plus chemotherapy
with chemotherapy alone in patients with unresectable liver
metastases of colorectal cancer.8
While robust randomized clinical trial data remains the
essential basis of all evidence-based medicine, it is
becoming increasingly important to supplement these
studies with more broadly inclusive, contextualized ‘real
world’ observational studies.9 These take into account the
preferences of patients and oncologists and withdrawal
from chemotherapy in patients with significant side effects.
Expert opinion has suggested that if provided in the usual
UK context of management by multidisciplinary teams
(MDTs) involving highly specialised liver surgical services,
resection rates following downsizing chemotherapy com-
bined with cetuximab could even exceed those seen in clin-
ical trials.4
To date there have been no observational studies of the
outcomes achieved with downsizing chemotherapy and ce-
tuximab for colorectal liver metastases in UK clinical prac-
tice. It has been acknowledged that liver resection rate is a
key outcome measure for this treatment and also recom-
mended that patients receiving it should be managed only
by MDTs that involve highly specialised liver surgical ser-
vices.4 Hence, this multi-centre retrospective observational
study was conducted in 7 UK NHS specialist liver surgical
centres with a primary objective of estimating theproportion of patients with unresectable liver metastases
who underwent liver resection following downsizing treat-
ment with chemotherapy plus cetuximab. A secondary
objective was to evaluate the health care process by which
the treatment was provided in normal UK practice.
Methods
Prior to commencement of the study at each centre, local
NHS Trust Research and Development (R&D) management
approval was obtained. Approval from an Independent
Ethics Committee (IEC) was not required due to new Gover-
nance Arrangements for UK Department of Health Research
Ethics Committees, effective from September 2011.10 These
allow studies involving the use of anonymised data collected
by clinicians who already have access to identifiable
records without IEC review or explicit patient consent.11
All patients meeting the inclusion/exclusion criteria
were selected for inclusion in the study, by clinicians
involved in their care within each centre, from clinical re-
cords and databases. There was no random sampling of
subjects. Patients were included if: they had mCRC with
metastases confined to the liver, defined as unresectable
at first review by the specialist MDT; the specialist MDT
review was after publication of NICE TA176 in August
2009 and they received downsizing chemotherapy and ce-
tuximab, starting cetuximab between Oct 2009eApr
2012. Patients were excluded if they had been enrolled in
a clinical trial or had received privately funded healthcare,
as these patients would not represent normal clinical prac-
tice in the NHS.
Data on patient and disease characteristics, resection
rates, concomitant chemotherapy and response rates were
collected retrospectively from medical records and hospital
databases at each participating hospital. Where necessary,
missing data were requested from other healthcare pro-
viders, most commonly referral centres and satellite centres
providing chemotherapy administration, for details of
chemotherapy and cetuximab prescribing.
For the evaluation of the health care process by which
downsizing chemotherapy with cetuximab was managed,
the participating centres were each asked to provide a ser-
vice profile to describe the MDT structure, including
specialist representation and workload.
Data collection was undertaken by members of the clin-
ical team at each centre from February to November 2012.
Prospective follow-up is ongoing to determine 5 year
survival.
ResultsStudy centresService profiles were provided by all seven centres. Six
described their MDT structure as hepatobiliary or hepato-
pancreatobiliary; three held hepatobiliary MDT meetings
Table 2
Resection rate and outcome.
Liver resection outcomes No. of patients % (n ¼ 60) SE 95% CI
R0 17 28% 5.8% 17% 40%
R1 7 12% 4.1% 4% 23%
R2 1 2% 1.7% 0% 10%
Other 2 3% 2.3% 0% 12%
Unknown 2 3% 2.3% 0% 12%
No resection 31 52% 6.5% 39% 64%
Total 60 100%
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MDTs met weekly. In addition, all centres provided MDT
review dates for all patients in the study. The median num-
ber of referral centres per MDT was 11.0 (Interquartile
range (IQR) 6.3e14.3). Only one centre performed liver
transplants. The median annual number of liver resections
performed for mCRC per centre was 80.0 (IQR
70.0e100.0), representing 44%e93% of all liver resections
performed annually.Study sampleAnonymised data were received for 64 patients. Four pa-
tients were excluded: one for metastases not confined to the
liver, one due to enrollment in a clinical trial and two due to
private healthcare for mCRC. Hence 60 patients were
included in the study (range 5e12 per centre).
Seventy-five percent (45/60) of the study sample were
male and the mean (SD) age at first downsizing chemo-
therapy infusion was 62 (11) years. Seventy-seven percent
(46/60) had synchronous presentation of CRC and
mCRC. In 52% (31/60) the primary tumour had been re-
sected prior to MDT review (Table 1).Primary endpoint
Resection rate
Twenty-nine (48%) patients underwent liver resection
following downsizing treatment including cetuximab
(95% CI 36e61%). Five of 11 patients who received
irinotecan-based chemotherapy and 24/49 of those who
received oxaliplatin-based chemotherapy underwent liver
resection.Secondary endpoints
Resection outcome
Of the 29 resected patients 17 (59%, or 28% of the




N (%) Males 45 (75%)











N (%) with primary tumour resected prior to specialist
MDT review
31 (52%)with an R0 (clear/negative margins) outcome. A further 7
(24% or 12% of the whole sample, 95% CI 4e23%) had
a R1 outcome (presence of microscopic tumour invasion
of the resection margin (tumour-free margin 0 mm)12)
(Table 2).
Range of downsizing chemotherapy regimens
Forty-nine (82%) patients received an oxaliplatin-based
chemotherapy regimen and in 11 (18%) chemotherapy
was irinotecan-based (Table 3).
Dose density of cetuximab
Of the 18 patients with complete cetuximab dosing data,
the median total dose of cetuximab administered was
5180 mg (IQR 4049e7175). The median weekly dose of
cetuximab administered was 207 mg/m2 (IQR 176e230),
excluding the loading dose.
Duration of downsizing
In the 27 patients with first and last chemotherapy infu-
sion dates recorded, median duration of chemotherapy was
ten weeks (IQR 9e20) and in the 35 patients with first and
last cetuximab infusion dates recorded, median duration of
cetuximab was 11 weeks (IQR 8e16).
Complete response (CR) following downsizing
In the 33 patients for whom a pathologic response was
recorded, nine (27%) patients had a complete response
and 24 (73%) did not.
Time to surgical intervention
In the 29 patients who underwent liver resection, median
time from first infusion of cetuximab until liver resection
was 23 weeks (IQR 19e30). Only 13 patients who under-
went liver resection had complete cetuximab dosing data;
median time from last infusion of cetuximab until liver
resection in these patients was 15 weeks (IQR 11e18). Me-
dian time from first cetuximab infusion to first ‘resectable’
scan result was 12 weeks (IQR 9e17) (n ¼ 26 with scans
indicating liver resectable).
KRAS testing
All 60 patients underwent KRAS testing. The median
time from blood sampling to receipt of the KRAS result
was eight days (IQR 7e13) (n ¼ 27 with complete dates).
Table 3
Chemotherapy regimens.
Chemotherapy regimen No. of patients % (n ¼ 60) SE 95% CI
FOLFOX4 10 17% 4.8% 7% 26%
FOLFOX6 3 5% 2.8% 1% 14%
FOLFOX6 modified 14 23% 5.5% 13% 34%
FOLFIRI 8 13% 4.4% 6% 24%
Other, specified 26 43% 6.4% 31% 56%
Note: Chemotherapy regimens are not mutually exclusive, 1 patient received FOLFOX4 followed by FOLFOX6.
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appropriate in all cases. Use of cetuximab in KRAS wt pa-
tients was appropriate at this time, the licence was subse-
quently updated to use of cetuximab in RAS wt patients
only.
Overall survival
The 24 month survival of the entire patient group is
shown in Fig. 1 based on whether patients were resected.
Twenty-nine patients underwent liver resection; of these
19 (66%) were alive at this time. Among all 60 patients
who received cetuximab and chemotherapy, there was one
death within 15 weeks of the first dose of cetuximab (ie
within four weeks of the median end of cetuximab treat-
ment), in a patient who received FOLFOX6 modifiedFigure 1. Kaplan Meier Survival Plot: survival to 2chemotherapy with cetuximab. The patient who died suf-
fered a post-operative bleed. Thirty-one patients did not un-
dergo liver resection; of these 13 (42%) were alive at 24
months. The apparent difference between the two observed
proportions (66% vs 42%, p ¼ 0.0577) (Fisher’s exact test),
at 24 months does not quite reach statistical significance
due to the small sample sizes.
Discussion
This was a retrospective observational study of the pro-
cesses and outcomes associated with downsizing chemo-
therapy plus cetuximab in the treatment of patients with
initially unresectable colorectal liver metastases. The re-
sults show that almost half (48%) of the patients who4 months from start of downsizing therapy.
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tuximab underwent liver resection, on average after 12
weeks’ treatment. Over half of these (59% of those under-
going resection or 28% of all the patients) had a R0
outcome of resection, which is similar to the results of
the CELIM interventional study7 in which 34% (36/106)
(95% CI 25e44) had a R0 outcome and a randomized
controlled trial8 with 26% (18/70) R0 outcomes. All three
studies are relatively small, producing results with wide
confidence intervals, but taken together, the similarity of
the results would suggest that chemotherapy and cetuximab
can facilitate a curative resection in a quarter to one third of
patients whose liver metastases were initially deemed unre-
sectable by a specialist MDT. Stratification of resection rate
by chemotherapy regimen received was not planned due to
the small size of the study. However, post-hoc comparison
of resection rate in the small group of patients treated with
irinotecan-based chemotherapy with those treated with
oxaliplatin-based chemotherapy did not add support to pre-
vious work suggesting that cetuximab with oxaliplatin-
based chemotherapy may be an undesirable combination.13
To date 24 months’ survival data are available for our
study and with this relatively short follow up and the small
sample size the apparent difference between patients who
did and did not undergo liver resection does not quite
achieve statistical significance, with 66% and 42% of pa-
tients respectively surviving at 24 months from the first
chemotherapy infusion. Survival at two years was higher
(85%) in patients who underwent resection in a much
larger, National Cancer Data Repository study.14 However,
this covered patients undergoing liver resection for colo-
rectal metastases and measured survival from colorectal
tumour resection not from downsizing chemotherapy as
in our study, it is unclear whether it included patients
receiving downsizing chemotherapy for previously unre-
sectable disease. In that study more patients who underwent
liver resection survived for 24 months than those who did
not (85% vs 24% respectively); at five years the difference
was even more marked (45% vs 9% respectively) and sur-
vival of resected patients was similar to patients with stage
III disease (45% vs 42% respectively). More recently, five
year survival results of the CELIM study showed that
46% of patients who had a R0 resection following downsiz-
ing chemotherapy and cetuximab survived for five years
compared with only 19% of those who did not have an
R0 resection.
15 These results support the case for ensuring
that all those who could undergo resection are offered it,
and our preliminary survival results further support the in-
clusion of those who require downsizing chemotherapy to
achieve resection. The results apply to patients with
initially unresectable liver-limited metastases and should
not be extrapolated to patients with operable disease in
whom the use of biological agents is not recommended.
Our study was not designed to compare survival of pa-
tients who received downsizing chemotherapy and cetuxi-
mab but who did not go on to resection, with survival ofsimilar patients not offered downsizing or resection. Previ-
ous work has shown that addition of cetuximab to the
chemotherapy regimens commonly used for downsizing re-
sulted in longer progression-free survival among patients
with KRAS wild-type.15 The 24 month survival of 42%
of unresected patients in our study compares favourably
with the results of the previous studies and suggests that pa-
tients embarking on a downsizing regimen are not disad-
vantaged if they do not proceed to resection.
A secondary objective of this study was to evaluate the
health care processes associated with delivery of downsiz-
ing chemotherapy and cetuximab. In particular whether
the need for KRAS testing to determine the suitability of
cetuximab for each patient due to receive downsizing
chemotherapy was causing delay in chemotherapy initia-
tion. However, we found that KRAS testing was routinely
and efficiently conducted, not delaying chemotherapy and
cetuximab start.
A further previously recognized4 important factor for
ensuring optimal management of these patients is specialist
MDT involvement in decision making regarding resect-
ability and the need for downsizing treatment. Patients
included in this study were managed by a specialist
MDT, meeting frequently, with routine, efficient KRAS
testing at the time the study was conducted (now RAS
testing) to ensure appropriate of cetuximab treatment. Our
study has shown this ‘package’ results in a resection rate
similar to that achieved in clinical trials. This reflects a pre-
vious study in one centre16 which showed that management
of patients without the involvement of a specialist liver
MDT leads to patients being denied potentially curative
treatments as some who could undergo resection are not
referred if decisions are taken by non-specialists.Study limitationsThe retrospective design of this study relies on the
completeness of clinical records with respect to the study
dataset. Complete study data was not available for all pa-
tients and as we have not attempted to impute missing
data, several analyses have been conducted on data from
fewer than half the patients in the study. This obviously rai-
ses the possibility of misleading results arising from this
incomplete data if those with missing data are different
from those with evaluable data. Data were missing espe-
cially for chemotherapy and cetuximab prescribing, which
was commonly undertaken at referring or satellite centres
from whom requested data sharing was incomplete. How-
ever data were available for the primary endpoint for all pa-
tients in the study.
Only a relatively short duration of survival follow up is
available to date due to the recent introduction of cetuxi-
mab into use outside clinical trials: we recognize that the
use of resection rate as our main endpoint is a surrogate
for the outcome which is most meaningful to patients and
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aim of reporting five year survival in due course.
The licence for cetuximab was updated in December
2013 from KRAS wt to RAS wt, which means that there
may have been a number of patients that received cetuxi-
mab treatment in this study that may not have benefitted.
Approximately 10% of the total population have been
found to harbor additional KRAS and NRAS mutations in
addition to KRAS exon 2 mutations.17e19 Further refine-
ment of the patient population to RAS wt would give a
more accurate reflection of the results.
Our study did not include any assessment of patients’
quality of life (QoL) associated with the interventions stud-
ied (which may be a more meaningful endpoint for patients
even than survival) due to the retrospective design and the
lack of a routinely-used measure of QoL. This is particu-
larly important since 52% of patients did not proceed to
resection and did not therefore receive potentially curative
treatment. This could be addressed with a prospective
observational study.
In spite of these limitations,wenevertheless believe that the
results we report here offer a worthwhile insight into the out-
comes of downsizing with chemotherapy and cetuximab.
Conclusion
In specialist liver surgical centres, where patients are
evaluated and prepared for liver resection, optimal manage-
ment by a specialist (either hepatobiliary or hepatopancrea-
tobiliary) MDT using KRAS testing (now RAS testing),
cetuximab and oxaliplatin- or irinotecan-based chemo-
therapy results in outcomes comparable with those
achieved in clinical trials.Acknowledgments
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